Several Phase I-II trials using monoclonal antibodies against checkpoint proteins have shown that targeting PD1 or PD-L1 with monoclonal antibodies is a viable therapeutic invention for patients with recurrent or metastatic NPC (137, 138). The gene discussed is PDCD1; the disease is nasopharyngeal carcinoma.